Medical Devices

A novel stent designed specifically for the brain's veins shows immediate success in its first human tests, offering new hope for a debilitating condition.

A landmark European approval for Elfabrio allows stable Fabry disease patients to switch to monthly infusions, promising greater freedom and lower healthcare strain.

As electroCore preps its 2025 financial report, all eyes are on its product growth, the new Quell device, and its path to profitability in the booming bioelectronic market.

Medicus Pharma's microneedle patch for basal cell carcinoma clears nearly three-quarters of lesions, offering a potential non-surgical alternative to the scalpel.

A new surgical robot from Beijing's Healinno Tech uses AI and a high-pressure waterjet to treat prostate issues with unprecedented precision and safety.

With new data on CUE-401, a novel therapy inspired by Nobel-winning science, Cue Biopharma makes a high-stakes play to redefine autoimmune treatment.

Despite lower annual revenue, 3D Systems reports a full-year profit driven by a major divestiture and strong growth in healthcare and aerospace sectors.

A year after rebranding from FibroGen, Kyntra Bio's first full-year report will test if its lean strategy can fuel its ambitious oncology pipeline.

A new non-thermal ablation technology shows long-term success in shrinking thyroid nodules with high patient satisfaction, potentially disrupting surgical norms.

IDEAYA Biosciences begins a key trial for its targeted therapy IDE892, aiming to conquer hard-to-treat tumors and pivoting to focus on its proprietary assets.

An in-depth look at the Nooro foot massager reveals a gap between its marketing claims, FDA clearance, and a pattern of customer service complaints.

Amid rising avian flu concerns, Canada secures millions of next-gen cell-based vaccines, upgrading its pandemic response arsenal for faster protection.

Eli Lilly and the WHO Foundation have launched a new collaboration to strengthen health systems and combat the escalating obesity crisis in underserved regions.

French pharma giant Servier acquires Day One Biopharmaceuticals, gaining a breakthrough pediatric cancer drug and signaling a major push into rare oncology.

Dr. Pietro Garbelli's award-winning book offers a crucial roadmap for responsibly integrating AI, balancing high-tech innovation with patient trust.

A landmark court decision certifies a massive class action against Johnson & Johnson, alleging its Baby Powder caused cancer and the company misled consumers.

The U.S. Army Medical Department's top-tier partnership with nurse anesthetists signals a new era for military healthcare readiness and professional recognition.

A new drug for Raynaud's phenomenon in scleroderma patients significantly boosts attack-free days, offering hope despite missing its primary trial goal.

Allarity Therapeutics lands a crucial $20M debt deal to push its unique ovarian cancer drug, stenoparib, through late-stage trials and extend its runway to 2028.

NeuroPace will present its RNS System at the Leerink conference, a key moment for the company to showcase its epilepsy treatment to top investors.